EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Qlife Holding AB's Enterprise Value is kr63.14 Mil.
Qlife Holding AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-12.74 Mil. Therefore, Qlife Holding AB's EV-to-FCF for today is -4.96.
The historical rank and industry rank for Qlife Holding AB's EV-to-FCF or its related term are showing as below:
OSTO:QLIFE'
s EV-to-FCF Range Over the Past 10 Years
Min: -385.52 Med: -3.33 Max: -0.12
Current: -5.01
During the past 7 years, the highest EV-to-FCF of Qlife Holding AB was -0.12. The lowest was -385.52. And the median was -3.33.
OSTO:QLIFE's EV-to-FCF is ranked worse than 100% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 23.12
vs OSTO:QLIFE: -5.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Qlife Holding AB (OSTO:QLIFE) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Qlife Holding AB's PE Ratio (TTM) for today is calculated as:
Qlife Holding AB's share price for today is kr1.93.
Qlife Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.238.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Qlife Holding AB EV-to-FCF Related Terms
Qlife Holding AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Qlife Holding AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Qlife Holding AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qlife Holding AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qlife Holding AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Qlife Holding AB's EV-to-FCF falls into.
Qlife Holding AB's current Enterprise Value is kr63.14 Mil.
Qlife Holding AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-12.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qlife Holding AB (OSTO:QLIFE) has a EV-to-FCF of -4.96 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Qlife Holding AB and its competitors. According to the industry distribution chart, Qlife Holding AB ranks #999999 out of 418 companies in the Medical Devices & Instruments industry.
Is Qlife Holding AB's EV-to-FCF too high?
Qlife Holding AB's current EV-to-FCF is -4.96. Based on the distribution chart, Qlife Holding AB ranks #999999 out of 418 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Qlife Holding AB has a GF Score™ of 15/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qlife Holding AB ranks #999999 out of 418 companies for EV-to-FCF. This places Qlife Holding AB in the lower half of its industry. The industry median EV-to-FCF is 23.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.12, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Qlife Holding AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qlife Holding AB's current EV-to-FCF is -4.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.76, compared to a current price of kr1.93 — trading 153.9% above its estimated fair value. The current EV-to-FCF is -4.96. Qlife Holding AB's overall GF Score™ is 15/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current EV-to-FCF is -4.96 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued.
The current stock price of kr1.93 is trading 153.9% above its estimated GF Value™ of kr0.76.
GuruFocus considers Qlife Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:QLIFE:
EV-to-FCF: -4.96
GF Value™: kr0.76 vs. price of kr1.93 (153.9% above fair value)
No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
15GF Score
Get the complete analysis for OSTO:QLIFE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:QLIFE has been successfully added to your 
